Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Date of Report: September 29, 2025
Reporting Period: Event-based report for September 29, 2025
The filing discloses a corporate event regarding the submission of clinical trial results for peer review. The Company is a biopharmaceutical entity focused on developing treatments for neurodegenerative diseases.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing is strictly an event notification.
Material Changes
Item 8.01 Other Events: On September 29, 2025, the Company announced the submission of a manuscript to npj Dementia, a Nature Portfolio journal. The manuscript details the results of the Phase 2 MINDFuL trial for XPro1595, a selective soluble TNF neutralizer, in patients with Early Alzheimer's Disease with Inflammation (ADi).
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release (Exhibit 99.1) regarding the trial results. No specific financial guidance, forward-looking projections, or risk factor updates are included in the text of this 8-K.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the full text of the press release filed as Exhibit 99.1 for specific clinical trial data and statistical significance.
- Confirm the status of the peer review process for the manuscript submitted to npj Dementia.
- Review the Company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K contains no financial data.
- Monitor for any subsequent regulatory filings or announcements regarding the FDA or EMA based on the MINDFuL trial results.